Bullish
Pfizer declares $0.43 dividend; Scotiabank raises price target to $33
Pfizer's stock is experiencing positive momentum following the declaration of a $0.43 per share dividend for Q4 2026 and an increased price target from Scotiabank. These developments reflect investor confidence in Pfizer's financial health and growth prospects.
Key points
- Pfizer's board declares a $0.43 dividend for Q4 2026, marking the 352nd consecutive quarterly dividend.
- Scotiabank raises Pfizer's price target to $33 from $30, maintaining an Outperform rating.
- Pfizer's LITFULO shows significant improvement in facial and total body repigmentation in patients with nonsegmental vitiligo.
- Pfizer's Tilrekimig demonstrates significant skin clearance in Phase 2 atopic dermatitis study.
Sources
- Pfizer Declares Fourth-Quarter 2026 DividendPfizer · October 6, 2026
- Pfizer (FRA:PFE) Stock Price & OverviewStockAnalysis · October 6, 2026
- Pfizer's LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental VitiligoPfizer · October 2, 2026
- Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis StudyPfizer · October 1, 2026
AI-generated from public news sources. Not financial advice.
